S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
An All-In-One Guide for Trading Metals (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
An All-In-One Guide for Trading Metals (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
An All-In-One Guide for Trading Metals (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
An All-In-One Guide for Trading Metals (Ad)pixel
Putin accuses the West of sabotaging Baltic Sea pipelines
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:DBVT

DBV Technologies - DBVT Stock Forecast, Price & News

$1.77
-0.04 (-2.21%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.68
$1.80
50-Day Range
$1.77
$2.76
52-Week Range
$1.15
$5.60
Volume
22,725 shs
Average Volume
100,128 shs
Market Capitalization
$332.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.63

DBV Technologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
217.8% Upside
$5.63 Price Target
Short Interest
Bearish
0.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.41mentions of DBV Technologies in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.68) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

937th out of 1,093 stocks

Biological Products, Except Diagnostic Industry

152nd out of 171 stocks

DBVT stock logo

About DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Stock News Headlines

FDA Imposes Partial Hold On DBV Technologies' Phase III VITESSE Study
Recap: DBV Technologies Q2 Earnings
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Company Calendar

Last Earnings
8/01/2022
Today
10/01/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DBVT
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.63
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+217.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-97,810,000.00
Net Margins
-929.78%
Pretax Margin
-928.45%

Debt

Sales & Book Value

Annual Sales
$5.71 million
Book Value
$0.90 per share

Miscellaneous

Free Float
186,922,000
Market Cap
$332.85 million
Optionable
Optionable
Beta
1.52

Key Executives

  • Mr. Daniel Tassé (Age 62)
    CEO & Director
    Comp: $1.14M
  • Mr. Sébastien Robitaille (Age 52)
    Chief Financial Officer
    Comp: $339.08k
  • Dr. Pharis Mohideen (Age 57)
    Chief Medical Officer
    Comp: $690.3k
  • Mr. Pascal Wotling
    Chief Technical Operations Officer & Chief Quality Officer
  • Anne Pollak
    Head of Investor Relations
  • Ms. Michele F. Robertson
    Chief Legal Officer
  • Joseph Becker
    VP of Global Corp. Communications
  • Ms. Caroline Daniere (Age 47)
    Chief HR Officer & Chief of Staff
  • Dr. Wence Agbotounou
    Chief Clinical Trial Officer & Sr. VP
  • Ms. Lucie Mondoulet
    Sr. VP & Deputy CSO













DBVT Stock - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DBVT shares.
View DBVT analyst ratings
or view top-rated stocks.

What is DBV Technologies' stock price forecast for 2022?

6 brokers have issued 1-year target prices for DBV Technologies' shares. Their DBVT share price forecasts range from $1.50 to $10.00. On average, they predict the company's share price to reach $5.63 in the next twelve months. This suggests a possible upside of 217.8% from the stock's current price.
View analysts price targets for DBVT
or view top-rated stocks among Wall Street analysts.

How have DBVT shares performed in 2022?

DBV Technologies' stock was trading at $1.60 at the start of the year. Since then, DBVT shares have increased by 10.6% and is now trading at $1.77.
View the best growth stocks for 2022 here
.

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our DBVT earnings forecast
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) announced its quarterly earnings results on Monday, August, 1st. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The company had revenue of $1.53 million for the quarter, compared to analysts' expectations of $2.57 million. DBV Technologies had a negative trailing twelve-month return on equity of 57.09% and a negative net margin of 929.78%.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $1.77.

How much money does DBV Technologies make?

DBV Technologies (NASDAQ:DBVT) has a market capitalization of $332.85 million and generates $5.71 million in revenue each year. The company earns $-97,810,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83.

This page (NASDAQ:DBVT) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.